Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lin, Y.
Right arrow Articles by Hillensjö, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, Y.
Right arrow Articles by Hillensjö, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 4, 885-888, April 1999
© 1999 European Society of Human Reproduction and Embryology

Is there a difference in the function of granulosa–luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?

Yang Lin1,2,3, Jarl A. Kahn1,4 and Torbjörn Hillensjö2

1 Ciconia Clinics, Frydendalsvej 5, 1809 Frederiksberg C., Copenhagen, Denmark, 2 Fertility Center Scandinavia, Box 5418, S-402 29 Göteborg, Sweden

Gonadotrophin-releasing hormone (GnRH) regulates gonadotrophin release. It has been shown that GnRH may have a direct effect on the ovary, as the addition of GnRH to granulosa cell cultures inhibits the production of progesterone and oestradiol. Specific GnRH receptors have been found to be present in rat and human granulosa cells. Desensitization of the pituitary by GnRH agonist has become common in in-vitro fertilization (IVF) treatment, usually by a long protocol of 2–3 weeks. With the introduction of GnRH antagonists, which produce an immediate blockage of the GnRH receptors, a much shorter exposure is needed of 3–6 days. The aim of this study was to evaluate the effect of a GnRH agonist (buserelin) and a GnRH antagonist (cetrorelix) on the function of granulosa cells cultured in vitro from IVF patients. Women were treated by IVF randomized either to have buserelin nasal spray from the luteal phase in the previous cycle or cetrorelix from day 6 of the cycle. Both groups had ovarian stimulation with human menopausal gonadotrophin (HMG) 150 IU daily, i.e. HCG was administered when the follicles were larger than 17 mm, and aspirated 36 h later. Granulosa cells, separated and washed from large follicles containing ova, were pooled. After 48 h of pre-incubation, the granulosa cells were cultured for 4 days in medium with either added testosterone or cAMP with or without HCG, with change of medium after 2 days. The progesterone and oestradiol concentrations in the culture medium were measured by immunological assay, and cellular protein was measured by microprotein assay. The results showed that granulosa cells from women treated with GnRH antagonist (cetrorelix) responded earlier to the in-vitro hormone stimulation in terms of progesterone accumulation than women treated with the GnRH agonist (buserelin). This may have been due to difference in time of exposure to the analogue. The results may indicate that the luteal function is less impaired in GnRH antagonist treatment than in GnRH agonist treatment.

Key words: GnRH agonist/GnRH antagonist/granulosa cells/IVF/steroidogenesis

3 Present address: First Affiliated Hospital of Sun Yet Sen University of Medical Sciences, Guangzhou, 510080 China

4 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, University Hospital of Trondheim, N-7006 Trondheim, Norway


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Reproductive SciencesHome page
C. Metallinou, B. Asimakopoulos, A. Schroer, and N. Nikolettos
Gonadotropin-Releasing Hormone in the Ovary
Reproductive Sciences, December 1, 2007; 14(8): 737 - 749.
[Abstract] [PDF]

Home page
 Hum ReprodHome page
Y. S. Choi, S.-Y. Ku, B.-C. Jee, C.-S. Suh, Y. M. Choi, J. G. Kim, S. Y. Moon, and S. H. Kim
Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients
Hum. Reprod., August 1, 2006; 21(8): 2015 - 2021.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. A. Garcia-Velasco, V. Isaza, C. Vidal, A. Landazabal, J. Remohi, C. Simon, and A. Pellicer
Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix)
Hum. Reprod., December 1, 2001; 16(12): 2533 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
O. Ortmann, J.M. Weiss, and K. Diedrich
Embryo implantation and GnRH antagonists: Ovarian actions of GnRH antagonists
Hum. Reprod., April 1, 2001; 16(4): 608 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Dor, D. Bider, A. Shulman, J. Levron, S. Shine, S. Mashiach, and J. Rabinovici
Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro--results of a prospective, randomized in-vitro fertilization study
Hum. Reprod., June 1, 2000; 15(6): 1225 - 1230.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.